Substituted imidazolidines for treating a RNA virus infection

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• ring Z is phenylene or pyridinylene;
• ring Z′ is phenylene or pyridinylene;
• Z″ is —CH2— or —C(O)—;
• Rg is H, C1-C4 alkyl, C3-C6cycloalkyl, —CH2CHF2, or —C(O)CH3;
• Rh is H, C1-C4 alkyl, C3-C6cycloalkyl, —CH2CHF2, or —C(O)CH3;
• Q is —NH— or —O—;
• X2 is —C(O)—NRk—, —NR′k—C(O)—, —O—, —C(O)—, —S(O)2—, —C(S)—NH—, —CH2—NH—, -oxetan-3-ylene-NH, or 5- or 6-membered heterocyclyl;
• wherein the heterocyclyl comprises 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of O, S, and N;
• and
• wherein the heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of C1-C4 alkyl, halogen, —C(O)ORp, and ═O;
• Rk is H or CH3;
• R′k is H or CH3;
• each Rp is independently C1-C4 alkyl;
• Y2 is H, halogen, OH, morpholinyl, bridged morpholinyl, C5-C11 bicycloalkyl, adamantlyl, piperidinyl, C2-C4 alkenyl, —P(O)(ORa)(OR), 5-membered heteroaryl, or —CR1R2R3,
• wherein the heteroaryl comprises 1 or 2 heteroatom(s) independently selected from the group consisting of O and N;
• wherein the morpholinyl is optionally substituted by one or more substituents independently selected from the group consisting of C1-C4 alkyl and —CF3;
• wherein the bridged morpholinyl is optionally substituted by one or more independently selected halogen substituents;
• and
• wherein one —CH2— group of the piperidinyl is optionally replaced by one S(O)2 group;
• one of (i) and (ii) is satisfied:
• (i) R1 is H, Fz or C1-C4 alkyl;
• and
• R2 is H, Fz or C1-C4 alkyl;
• or
• (ii) R1 and R2, together with the carbon atom to which they are attached, form a C3-C8 cycloalkyl;
• wherein the C3-C8 cycloalkyl is optionally substituted by one or two independently selected C1-C4 alkyl substituents;
• wherein each C1-C4 alkyl substituent is optionally and independently substituted by one or more substituents independently selected from the group consisting of OH, halogen, CF3, CN, P(O)(ORa)(OR), ═O, and OC1-C4 alkyl;
• and
• wherein one or two —CH2— groups of the C3-C8 cycloalkyl are optionally and independently replaced by one or two groups independently selected from the group consisting of —O—, —NH—, —S—, and —S(O)2—;
• and
• R3 is H, Fz or C1-C4 alkyl, wherein one —CH2— group of the C1-C4 alkyl is optionally replaced by one —NH—;
• each R is independently C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, CF3, furanyl, halogen, CN, or OC1-C5 alkyl;
• wherein one —CH2— group of each C1-C4 alkyl is optionally and independently replaced by one group independently selected from the group consisting of —S(O)— and —S(O)2—;
• and
• wherein each C1-C4 alkyl is optionally and independently substituted by one or more OH substituents;
• each R′ is independently C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, CF3, furanyl, halogen, CN or OC1-C5 alkyl;
• wherein one —CH2— group of each C1-C4 alkyl is optionally and independently replaced by one group independently selected from the group consisting of —S(O)— and —S(O)2—;
• and
• wherein each C1-C4 alkyl is optionally and independently substituted by one or more OH substituents;
• each Ra is independently H or C1-C4 alkyl;
• each Rb is independently H or C1-C4 alkyl;
• n is 0, 1, 2, or 3;
• m is 0, 12 or 2;
• and
• m′ is 0, 1, or 2;
• with the proviso that no more than one of R1, R2, and R3 is H.